SEER Most cancers Stat Information: Ovarian Most cancers, N. C. I. B., MD (2018).
Most cancers Information and Figures 2018, Atlanta, GA: American Most cancers Society (2018).
Jacobs, I. et al. A threat of malignancy index incorporating CA 125, ultrasound and menopausal standing for the correct preoperative analysis of ovarian most cancers. Br J Obstet Gynaecol 97, 922–929, https://doi.org/10.1111/j.1471-0528.1990.tb02448.x (1990).
Sundar, S., Neal, R. D. & Kehoe, S. Analysis of ovarian most cancers. BMJ (Scientific analysis ed.) 351, h4443, https://doi.org/10.1136/bmj.h4443 (2015).
Rai, N. et al. Outcomes following implementation of symptom triggered diagnostic testing for ovarian most cancers. European journal of obstetrics, gynecology, and reproductive biology 187, 64–69, https://doi.org/10.1016/j.ejogrb.2015.02.011 (2015).
Jacobs, I. J. et al. Ovarian most cancers screening and mortality within the UK Collaborative Trial of Ovarian Most cancers Screening (UKCTOCS): a randomised managed trial. Lancet 387, 945–956, https://doi.org/10.1016/s0140-6736(15)01224-6 (2016).
Hentze, J. L., Hogdall, C. Okay. & Hogdall, E. V. Methylation and ovarian most cancers: Can DNA methylation be of diagnostic use? Molecular and medical oncology 10, 323–330, https://doi.org/10.3892/mco.2019.1800 (2019).
Reid, B. M., Permuth, J. B. & Sellers, T. A. Epidemiology of ovarian most cancers: a evaluate. Most cancers biology & drugs 14, 9–32, https://doi.org/10.20892/j.issn.2095-3941.2016.0084 (2017).
Elias, Okay. M., Guo, J. & Bast, R. C. Jr. Early Detection of Ovarian Most cancers. Hematology/oncology clinics of North America 32, 903–914, https://doi.org/10.1016/j.hoc.2018.07.003 (2018).
Vergote, I. et al. Neoadjuvant chemotherapy or major surgical procedure in stage IIIC or IV ovarian most cancers. The New England journal of drugs 363, 943–953, https://doi.org/10.1056/NEJMoa0908806 (2010).
Kehoe, S. et al. Major chemotherapy versus major surgical procedure for newly identified superior ovarian most cancers (CHORUS): an open-label, randomised, managed, non-inferiority trial. Lancet 386, 249–257, https://doi.org/10.1016/s0140-6736(14)62223-6 (2015).
Bristow, R. E., Tomacruz, R. S., Armstrong, D. Okay., Trimble, E. L. & Montz, F. J. Survival impact of maximal cytoreductive surgical procedure for superior ovarian carcinoma through the platinum period: a meta-analysis. Journal of medical oncology: official journal of the American Society of Scientific Oncology 20, 1248–1259, https://doi.org/10.1200/jco.2002.20.5.1248 (2002).
Martin, L. P. & Schilder, R. J. Administration of recurrent ovarian carcinoma: present standing and future instructions. Seminars in oncology 36, 112–125, https://doi.org/10.1053/j.seminoncol.2008.12.003 (2009).
Moufarrij, S. et al. Epigenetic remedy for ovarian most cancers: promise and progress. Scientific epigenetics 11, 7, https://doi.org/10.1186/s13148-018-0602-0 (2019).
Built-in genomic analyses of ovarian carcinoma. Nature 474, 609–615, https://doi.org/10.1038/nature10166 (2011).
Paige, A. J. & Brown, R. Pharmaco(epi)genomics in ovarian most cancers. Pharmacogenomics 9, 1825–1834, https://doi.org/10.2217/14622416.9.12.1825 (2008).
Jones, P. A. & Baylin, S. B. The epigenomics of most cancers. Cell 128, 683–692, https://doi.org/10.1016/j.cell.2007.01.029 (2007).
Mohammad, H. P., Barbash, O. & Creasy, C. L. Concentrating on epigenetic modifications in most cancers remedy: erasing the roadmap to most cancers. Nature drugs 25, 403–418, https://doi.org/10.1038/s41591-019-0376-8 (2019).
Pfister, S. X. & Ashworth, A. Marked for dying: focusing on epigenetic adjustments in most cancers. Nature evaluations. Drug discovery 16, 241–263, https://doi.org/10.1038/nrd.2016.256 (2017).
Mahmoud, A. M. & Ali, M. M. Methyl Donor Micronutrients that Modify DNA Methylation and Most cancers Consequence. Vitamins 11, https://doi.org/10.3390/nu11030608 (2019).
Herman, J. G. & Baylin, S. B. Gene silencing in most cancers in affiliation with promoter hypermethylation. The New England journal of drugs 349, 2042–2054, https://doi.org/10.1056/NEJMra023075 (2003).
Weber, M. & Schubeler, D. Genomic patterns of DNA methylation: targets and performance of an epigenetic mark. Present opinion in cell biology 19, 273–280, https://doi.org/10.1016/j.ceb.2007.04.011 (2007).
Koukoura, O., Spandidos, D. A., Daponte, A. & Sifakis, S. DNA methylation profiles in ovarian most cancers: implication in analysis and remedy (Overview). Molecular drugs experiences 10, 3–9, https://doi.org/10.3892/mmr.2014.2221 (2014).
Santillan, M. Okay. et al. Assortment of a lifetime: a sensible strategy to creating a longitudinal assortment of girls’s healthcare organic samples. European journal of obstetrics, gynecology, and reproductive biology 179, 94–99, https://doi.org/10.1016/j.ejogrb.2014.05.023 (2014).
Braun, P. R. et al. Genome-wide DNA methylation investigation of glucocorticoid publicity inside buccal samples. Psychiatry and medical neurosciences 73, 323–330, https://doi.org/10.1111/pcn.12835 (2019).
Schroeder, A. et al. The RIN: an RNA integrity quantity for assigning integrity values to RNA measurements. BMC molecular biology 7, 3, https://doi.org/10.1186/1471-2199-7-3 (2006).
Salinas, E. A. et al. A Prediction Mannequin for Preoperative Danger Evaluation in Endometrial Most cancers Using Scientific and Molecular Variables. Worldwide journal of molecular sciences 20, https://doi.org/10.3390/ijms20051205 (2019).
Aryee, M. J. et al. Minfi: a versatile and complete Bioconductor package deal for the evaluation of Infinium DNA methylation microarrays. Bioinformatics (Oxford, England) 30, 1363–1369, https://doi.org/10.1093/bioinformatics/btu049 (2014).
Rechache, N. S. et al. DNA methylation profiling identifies world methylation variations and markers of adrenocortical tumors. The Journal of medical endocrinology and metabolism 97, E1004–1013, https://doi.org/10.1210/jc.2011-3298 (2012).
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: an R package deal for evaluating organic themes amongst gene clusters. Omics: a journal of integrative biology 16, 284–287, https://doi.org/10.1089/omi.2011.0118 (2012).
Dietl, J. Revisiting the pathogenesis of ovarian most cancers: the central position of the fallopian tube. Arch Gynecol Obstet 289, 241–246, https://doi.org/10.1007/s00404-013-3041-3 (2014).
Labidi-Galy, S. I. et al. Excessive grade serous ovarian carcinomas originate within the fallopian tube. Nature communications 8, 1093, https://doi.org/10.1038/s41467-017-00962-1 (2017).
Vang, R., Shih, I. M. & Kurman, R. J. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62, 44–58, https://doi.org/10.1111/his.12046 (2013).
Gockley, A. A. & Elias, Okay. M. Fallopian tube tumorigenesis and medical implications for ovarian most cancers risk-reduction. Most cancers remedy evaluations 69, 66–71, https://doi.org/10.1016/j.ctrv.2018.06.004 (2018).
Marquez, R. T. et al. Patterns of gene expression in several histotypes of epithelial ovarian most cancers correlate with these in regular fallopian tube, endometrium, and colon. Scientific most cancers analysis: an official journal of the American Affiliation for Most cancers Analysis 11, 6116–6126, https://doi.org/10.1158/1078-0432.ccr-04-2509 (2005).
Klinkebiel, D., Zhang, W., Akers, S. N., Odunsi, Okay. & Karpf, A. R. DNA Methylome Analyses Implicate Fallopian Tube Epithelia because the Origin for Excessive-Grade Serous Ovarian Most cancers. Molecular most cancers analysis: MCR 14, 787–794, https://doi.org/10.1158/1541-7786.mcr-16-0097 (2016).
Eskander, R. N. The Epigenetic Panorama within the Therapy of Gynecologic Malignancies. American Society of Scientific Oncology instructional guide. American Society of Scientific Oncology. Annual Assembly 38, 480–487, https://doi.org/10.1200/edbk_200203 (2018).
Pisanic, T. R. 2nd et al. Methylomic Evaluation of Ovarian Cancers Identifies Tumor-Particular Alterations Readily Detectable in Early Precursor Lesions. Scientific most cancers analysis: an official journal of the American Affiliation for. Most cancers Analysis 24, 6536–6547, https://doi.org/10.1158/1078-0432.CCR-18-1199 (2018).
Bartlett, T. E. et al. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian most cancers evolution. Nature communications 7, 11620, https://doi.org/10.1038/ncomms11620 (2016).
Teschendorff, A. E. et al. An epigenetic signature in peripheral blood predicts energetic ovarian most cancers. PloS one 4, e8274, https://doi.org/10.1371/journal.pone.0008274 (2009).
Wei, S. H. et al. Methylation microarray evaluation of late-stage ovarian carcinomas distinguishes progression-free survival in sufferers and identifies candidate epigenetic markers. Scientific most cancers analysis: an official journal of the American Affiliation for. Most cancers Analysis 8, 2246–2252 (2002).
Wei, S. H. et al. Prognostic DNA methylation biomarkers in ovarian most cancers. Scientific most cancers analysis: an official journal of the American Affiliation for. Most cancers Analysis 12, 2788–2794, https://doi.org/10.1158/1078-0432.ccr-05-1551 (2006).
Pattamadilok, J. et al. LINE-1 hypomethylation stage as a possible prognostic issue for epithelial ovarian most cancers. Worldwide journal of gynecological most cancers: official journal of the Worldwide Gynecological Most cancers Society 18, 711–717, https://doi.org/10.1111/j.1525-1438.2007.01117.x (2008).
Wang, C. et al. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian most cancers. Most cancers analysis 74, 3084–3091, https://doi.org/10.1158/0008-5472.can-13-3198 (2014).
Shi, H. et al. Affiliation between RASSF1A promoter methylation and ovarian most cancers: a meta-analysis. PloS one 8, e76787, https://doi.org/10.1371/journal.pone.0076787 (2013).
Samudio-Ruiz, S. L. & Hudson, L. G. Elevated DNA methyltransferase exercise and DNA methylation following Epidermal Progress Issue stimulation in ovarian most cancers cells. Epigenetics 7, 216–224, https://doi.org/10.4161/epi.7.3.19273 (2012).
Mauffrey, P. et al. Progenitors from the central nervous system drive neurogenesis in most cancers. Nature 569, 672–678, https://doi.org/10.1038/s41586-019-1219-y (2019).
Madeo, M. et al. Most cancers exosomes induce tumor innervation. Nature communications 9, 4284, https://doi.org/10.1038/s41467-018-06640-0 (2018).
Kamiya, A. et al. Genetic manipulation of autonomic nerve fiber innervation and exercise and its impact on breast most cancers development. Nature neuroscience 22, 1289–1305, https://doi.org/10.1038/s41593-019-0430-3 (2019).
Li, N., Li, H., Cao, L. & Zhan, X. Quantitative evaluation of the mitochondrial proteome in human ovarian carcinomas. Endocrine-related most cancers 25, 909–931, https://doi.org/10.1530/erc-18-0243 (2018).
Huang, Z. et al. Emergence of epigenetic regulation of tight junction genes in recurrent serous epithelial ovarian most cancers. Most cancers analysis 75, 2236–2236, https://doi.org/10.1158/1538-7445.am2015-2236 (2015).
Gloss, B. S. & Samimi, G. Epigenetic biomarkers in epithelial ovarian most cancers. Most cancers letters 342, 257–263, https://doi.org/10.1016/j.canlet.2011.12.036 (2014).
Wanderley, C. W. et al. Paclitaxel Reduces Tumor Progress by Reprogramming Tumor-Related Macrophages to an M1 Profile in a TLR4-Dependent Method. Most cancers analysis 78, 5891–5900, https://doi.org/10.1158/0008-5472.can-17-3480 (2018).
Block, M. S. et al. MyD88 and TLR4 Expression in Epithelial Ovarian Most cancers. Mayo Clinic proceedings 93, 307–320, https://doi.org/10.1016/j.mayocp.2017.10.023 (2018).
Chen, J. et al. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian most cancers. PloS one 7, e42413, https://doi.org/10.1371/journal.pone.0042413 (2012).
Socha, M. J. et al. Aberrant promoter methylation of SPARC in ovarian most cancers. Neoplasia (New York, N.Y.) 11, 126–135, https://doi.org/10.1593/neo.81146 (2009).
Hooda, J. et al. Early Lack of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Prompts Key Immune Pathways That Facilitate Development of Ovarian Most cancers. Most cancers analysis 79, 760–772, https://doi.org/10.1158/0008-5472.CAN-18-2297 (2019).
Ushijima, T. & Asada, Okay. Aberrant DNA methylation in distinction with mutations. Most cancers science 101, 300–305, https://doi.org/10.1111/j.1349-7006.2009.01434.x (2010).
Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in most cancers – a mechanism for early oncogenic pathway habit? Nature evaluations. Most cancers 6, 107–116, https://doi.org/10.1038/nrc1799 (2006).
Strathdee, G. et al. Demethylation of the MCJ gene in stage III/IV epithelial ovarian most cancers and response to chemotherapy. Gynecol Oncol 97, 898–903, https://doi.org/10.1016/j.ygyno.2005.03.023 (2005).
Su, H. Y. et al. Epigenetic silencing of SFRP5 is said to malignant phenotype and chemoresistance of ovarian most cancers by Wnt signaling pathway. Worldwide journal of most cancers. Journal worldwide du most cancers 127, 555–567, https://doi.org/10.1002/ijc.25083 (2010).
Nicholson, L. J. et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell dying however collateral sensitivity to arginine auxotrophy in ovarian most cancers. Worldwide journal of most cancers. Journal worldwide du most cancers 125, 1454–1463, https://doi.org/10.1002/ijc.24546 (2009).
Strathdee, G., MacKean, M. J., Illand, M. & Brown, R. A task for methylation of the hMLH1 promoter in lack of hMLH1 expression and drug resistance in ovarian most cancers. Oncogene 18, 2335–2341, https://doi.org/10.1038/sj.onc.1202540 (1999).
Yap, O. W., Bhat, G., Liu, L. & Tollefsbol, T. O. Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian most cancers cells. Anticancer Res 29, 139–144 (2009).
Strauss, J. & Figg, W. D. Utilizing Epigenetic Remedy to Overcome Chemotherapy Resistance. Anticancer Res 36, 1–4 (2016).
Fu, S. et al. Section 1b-2a research to reverse platinum resistance by use of a hypomethylating agent, azacitidine, in sufferers with platinum-resistant or platinum-refractory epithelial ovarian most cancers. Most cancers 117, 1661–1669, https://doi.org/10.1002/cncr.25701 (2011).
Fang, F. et al. A section 1 and pharmacodynamic research of decitabine together with carboplatin in sufferers with recurrent, platinum-resistant, epithelial ovarian most cancers. Most cancers 116, 4043–4053, https://doi.org/10.1002/cncr.25204 (2010).
Glasspool, R. M. et al. A randomised, section II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) together with carboplatin vs carboplatin alone in sufferers with recurrent, partially platinum-sensitive ovarian most cancers. British journal of most cancers 110, 1923–1929, https://doi.org/10.1038/bjc.2014.116 (2014).
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D’Andrea, A. D. Homologous Recombination Deficiency: Exploiting the Basic Vulnerability of Ovarian Most cancers. Most cancers discovery 5, 1137–1154, https://doi.org/10.1158/2159-8290.cd-15-0714 (2015).
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B. & Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian most cancers sufferers. Scientific most cancers analysis: an official journal of the American Affiliation for Most cancers Analysis 10, 4420–4426, https://doi.org/10.1158/1078-0432.ccr-03-0732 (2004).
